{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:38:44Z","timestamp":1790379524319,"version":"4.1.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n Ceftolozane\/tazobactam, a novel antimicrobial agent with activity against\n Pseudomonas aeruginosa<\/jats:named-content>\n (including drug-resistant strains) and other common Gram-negative pathogens (including most extended-spectrum-\u03b2-lactamase [ESBL]-producing\n Enterobacteriaceae<\/jats:named-content>\n strains), and comparator agents were susceptibility tested by a reference broth microdilution method against 7,071\n Enterobacteriaceae<\/jats:named-content>\n and 1,971\n P. aeruginosa<\/jats:named-content>\n isolates. Isolates were collected consecutively from patients in 32 medical centers across the United States during 2011 to 2012. Overall, 15.7% and 8.9% of\n P. aeruginosa<\/jats:named-content>\n isolates were classified as multidrug resistant (MDR) and extensively drug resistant (XDR), and 8.4% and 1.2% of\n Enterobacteriaceae<\/jats:named-content>\n were classified as MDR and XDR. No pandrug-resistant (PDR)\n Enterobacteriaceae<\/jats:named-content>\n isolates and only one PDR\n P. aeruginosa<\/jats:named-content>\n isolate were detected. Ceftolozane\/tazobactam was the most potent (MIC\n 50\/90<\/jats:sub>\n , 0.5\/2 \u03bcg\/ml) agent tested against\n P. aeruginosa<\/jats:named-content>\n and demonstrated good activity against 310 MDR strains (MIC\n 50\/90<\/jats:sub>\n , 2\/8 \u03bcg\/ml) and 175 XDR strains (MIC\n 50\/90<\/jats:sub>\n , 4\/16 \u03bcg\/ml). Ceftolozane\/tazobactam exhibited high overall activity (MIC\n 50\/90<\/jats:sub>\n , 0.25\/1 \u03bcg\/ml) against\n Enterobacteriaceae<\/jats:named-content>\n and retained activity (MIC\n 50\/90<\/jats:sub>\n , 4\/>32 \u03bcg\/ml) against many 601 MDR strains but not against the 86 XDR strains (MIC\n 50<\/jats:sub>\n , >32 \u03bcg\/ml). Ceftolozane\/tazobactam was highly potent (MIC\n 50\/90<\/jats:sub>\n , 0.25\/0.5 \u03bcg\/ml) against 2,691\n Escherichia coli<\/jats:named-content>\n isolates and retained good activity against most ESBL-phenotype\n E. coli<\/jats:named-content>\n isolates (MIC\n 50\/90<\/jats:sub>\n , 0.5\/4 \u03bcg\/ml), but activity was low against ESBL-phenotype\n Klebsiella pneumoniae<\/jats:named-content>\n isolates (MIC\n 50\/90<\/jats:sub>\n , 32\/>32 \u03bcg\/ml), explained by the high rate (39.8%) of meropenem coresistance observed in this species phenotype. In summary, ceftolozane\/tazobactam demonstrated high potency and broad-spectrum activity against many contemporary\n Enterobacteriaceae<\/jats:named-content>\n and\n P. aeruginosa<\/jats:named-content>\n isolates collected in U.S. medical centers. Importantly, ceftolozane\/tazobactam retained potency against many MDR and XDR strains.\n <\/jats:p>","DOI":"10.1128\/aac.01802-13","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T23:08:58Z","timestamp":1381187338000},"page":"6305-6310","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":190,"title":["Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)"],"prefix":"10.1128","volume":"57","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Division of Infectious Diseases, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-10"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.03.021"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01104-09"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.05.019"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00912-09"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp193"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.02.004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.14.3.414"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.2.199"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2011.05.020"},{"key":"e_1_3_2_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 23rd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01590-12"},{"key":"e_1_3_2_17_2","unstructured":"EUCAST January 2013. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 2 January 2013."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01753-09"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks246"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-13"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01802-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01802-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:27:06Z","timestamp":1645464426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01802-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1128\/AAC.01802-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01802-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"2013-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}